Compare TK & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TK | SVRA |
|---|---|---|
| Founded | 1973 | 2007 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 1995 | 2009 |
| Metric | TK | SVRA |
|---|---|---|
| Price | $10.70 | $5.73 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $7.33 |
| AVG Volume (30 Days) | 506.6K | ★ 1.8M |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | ★ 15.21% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $430.87 |
| P/E Ratio | $13.43 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.12 | $1.98 |
| 52 Week High | $14.38 | $7.01 |
| Indicator | TK | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 32.98 | 60.63 |
| Support Level | $9.11 | $4.77 |
| Resistance Level | $14.12 | $6.15 |
| Average True Range (ATR) | 0.51 | 0.28 |
| MACD | -0.06 | 0.07 |
| Stochastic Oscillator | 8.14 | 69.28 |
Teekay Corp Ltd provides international crude oil marine transportation and other marine services. It also offers offshore oil production, storage, and offloading services, under long-term, fixed-rate contracts. The company has two primary lines of business: Marine services and tankers. It manages these businesses for the benefit of all stakeholders. The company serves energy and utility companies, oil traders, large oil and LNG consumers, petroleum product producers, government agencies, and various other entities that depend upon marine transportation.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).